Otsuka Pharmaceutical Co., Ltd.

ABILIFY Maintena

ABILIFY Maintena

ABILIFY Maintena, a prolonged release aquaeous suspension for intramuscular injection

ABILIFY Maintena is administered by injection once monthly. It is a long-acting formulation of the antipsychotic ABILIFY (aripiprazole). In 2013, ABILIFY Maintena was launched in the U.S. with an indication for schizophrenia and subsequently has become available in over 50 countries. In 2017 the product was approved for use in treatment of bipolar I disorder in the U.S. and Canada. In Japan, it was launched in 2015 for the treatment of schizophrenia and approved for the additional indication of bipolar I disorder in 2020.